Kymera Therapeutics Inc. has patented new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 1 (IRAK-4)-targeting moiety via linker.

Work at IFM Due Inc. has led to the identification of stimulator of interferon genes protein receptor (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, systemic lupus erythematosus, autoinflammatory interferonopathy, rheumatoid arthritis and Aicardi-Goutieres syndrome.

Stablix Inc. has described new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Scinnohub Pharmaceutical Co. Ltd. has patented new compounds.

Deciphera Pharmaceuticals LLC has patented new serine/threonine-protein kinase B-raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1; c-Raf) inhibitors reported to be useful for the treatment of cancer.

Humanwell Healthcare (Group) Co. Ltd. has developed new heterocyclic compounds acting as angiotensin AT2 receptor antagonists reported to be useful for the treatment of neuropathy and neuropathic pain.

Quanta Therapeutics Inc. has identified new pyrimidine-based GTPase KRAS G12D and G12V mutant inhibitors potentially useful for the treatment of cancer.

Astrazeneca AB patents describe new proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety reported to be useful for the treatment of cancer.

Researchers from Northeastern University and the University of Georgia have synthesized new tetrahydroacridinone analogues.

Centre National de la Recherche Scientifique (CNRS) and Université Grenoble Alpes have developed new iridium complexes acting as photosensitizers for photodynamic therapy and reported to be potentially useful for the treatment of cancer.